Penn Medicine Provider
Gastroenterology
Neilanjan Nandi, MD, FACG, AGAF, FACP
5.0
(426)
Accepting new patients
Sees patients age 18 and up
Penn Gastroenterology Radnor
View 2 additional locations

About me

  • Co-Section Head and Clinical Program Director, Penn Inflammatory Bowel Diseases Program
  • Associate Professor of Clinical Medicine (Gastroenterology)

Education and training

  • Medical School: Northwestern University Feinberg School of Medicine
  • Residency: Thomas Jefferson University Hospital
  • Fellowship: Jackson Health System - Jackson Memorial

What my patients think about me

Average Rating
5.0

426 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

May 2025
5.0
5.0
great doctor
April 2025
5.0
5.0
excellent compassionate care. truly listens to his patients
April 2025
5.0
5.0
i waited 53 minutes, but provider never showed, so i had to leave for my next appt
April 2025
5.0
5.0
professional expertise in the gi field for medical care lead to easy understanding of what was going on and answered all questions as best as possible

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Nandi is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Sehgal P, Khanna T, Profka K, Pickett-Blakely O, Nandi N, Rashid F, Bewtra M, Lewis J, Lichtenstein G, Aberra F. Safety and clinical effectiveness of GLP1 agonists in inflammatory bowel disease patients. , Clin Gastroenterol Hepatol, 25: 2025,S1542-3565(25)00073-4.


Elias S, Nandi N, Grover L, Fourie S, Newman KL Addressing Factors that Impact Sexual Well-Being and Intimacy in IBD Patients , Curr Gastroenterol Rep: 2025,1-10


Brittaney Bonhomme, BS, Neilanjan Nandi, MD, †, Shivali Berera, MD, Helen Lee, MD, Galen Leung, MD, Chung SangTse, MD, Alexandra Weiss, MD, Lisa Nessel, MSS, MLSP, Yue Ren, MA, Hongzhe Li, PhD, Faten N. Aberra, MD, MSCE, James D. Lewis, MD, MSCE Greater Fatigue and Reduced Neurocognitive Speed With Symptomatic Crohn’s Disease. , Crohn's & Colitis 360, 7(1): 2024,1-12


Sehgal P, Khanna T, Profka K, Pickett-Blakely O, Nandi N, Rashid F, Bewtra M, Lewis J, Lichtenstein G, Aberra F. Impact of GLP1 agonists on inflammatory biomarkers in patients with inflammatory bowel disease. , DDW, Poster Sa1950: 2024


Yarur AJ, Long M, Torres J, Nandi N, Cross RK, Abbatemarco AM, Blanco D, Niezychowski W, Crosby C, Wu J, Pradeep G, Goetsch M, Panaccione R. Body mass index does not affect the efficacy and safety of etrasimod in ulcerative colitis patients: a post hoc analysis from the ELEVATE UC clinical program. , American Journal of Gastroenterology., 119(10S): 2024,S1026-S1027


Toiv A, Saleh Z, Alsheik E, Venkat D, Nandi N, Zuchelli T. Digesting Digital Health: A study of appropriateness and readability of Chat GPT generated gastroenterological information. , Clinical and Translational Gastroenterology. , 15(11:e00765): 2024


Charan V, Mukherjee S, Nandi N, Weiss A, Schmoyer C. Evaluating AI-Language models in providing answers for inflammatory bowel disease (IBD) in pregnancy: A comparative analysis of GPT4, BARD and LLAMA2. , DDW, Poster Mo1883: 2024


Allison Ferris, Polina Gaisinskaya, Neilanjan Nandi. Approach to Diarrhea. , Primary Care: Clinics in Office Practice: 2023,447-459


Balasubramaniam M, Nandi N, Aswani-Omprakash T, Sebastian S, Sharma V, Deepak P; South Asian Ibd Alliance Board Of Directors. Identifying Care Challenges as Opportunities for Research and Education in Inflammatory Bowel Disease in South Asia , Gastroenterology, 163(5): 2022,1145-1150


Keerthana Kesavarapu, DO, Asta Zelenkauskaite, PhD, Neilanjan Nandi, MD, FACP Reach and Power of Physician-Initiated Tweets in a Twitter Inflammatory Bowel Disease Community , Crohn's & Colitis 360, 3(3:otab052): 2021